|
Vaccines Benefit Mainly Wealthy Countries--UN Report
UNITED NATIONS (Reuters) Nov 20 - Vaccinations have prevented millions of
deaths around the world but children in wealthy nations are getting the
lion's share of the shots--and the benefits, the United Nations said on
Wednesday.
While young people in rich countries have access to the latest and
costliest vaccines available, just 50% of children in sub-Saharan Africa are
immunized during their first year of life against common diseases like
tuberculosis, measles, tetanus and whooping cough, three UN agencies said in
a joint report.
In poor and isolated parts of some developing nations, vaccines reach
fewer than 1 in 20 children, said the report by the World Health
Organization, the World Bank and the UN Children's Fund.
"Immunization, as powerful and successful as it is, has yet to reach its
enormous potential," the report said. "The right to protection from
preventable diseases is the right of every child and it is well within our
collective capacity to realize that right."
A quarter of the world's children lack protection from common preventable
diseases, according to the report. Nearly 3 million people--2 million of
them children--die every year from those diseases, it said.
While vaccines for diseases like meningitis and pneumonia are widely
available in rich nations, children in developing countries are dying from
these same diseases, it found.
According to the report, rich nations annually provide $1.56 billion in
aid to immunization programs. An extra $250 million a year would cover the
cost of basic vaccines for at least another 10 million children, it said. A
further $100 million would cover the cost of newer vaccines for these
children, including those protecting against hepatitis B and Haemophilus
influenzae type B (Hib).
Hepatitis B now causes 520,000 deaths a year worldwide while Hib kills
450,000 children in developing countries, the report said.
Developing nations, which currently spend as little as $6 a year per
person on health including immunizations, also need to increase their
spending, it said.
The low levels of protection against diseases that ravage primarily the
developing world are also having a significant impact on vaccine research,
the study found.
Drug companies find they have little incentive to invest in vaccines for
diseases that attack mostly the poor, such as Shigella dysentery, dengue,
Japanese encephalitis, leishmaniasis, schistosomiasis and cholera, the
report said.
It called on pharmaceutical firms--with help from wealthy governments--to
redouble their efforts to develop vaccines against malaria, which kills
about one million people each year, and tuberculosis, which killed 1.7
million people in 2000.
| |
|

Reuters Health Information 2002. © 2002 Reuters Ltd.
Republication or redistribution of Reuters content, including by
framing or similar means, is expressly prohibited without the prior
written consent of Reuters. Reuters shall not be liable for any errors
or delays in the content, or for any actions taken in reliance
thereon. Reuters and the Reuters sphere logo are registered trademarks
and trademarks of the Reuters group of companies around the world.

|
|